Clinical trials: Moderate to Severe Dry Eye
Dry Eye Disease
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.
- Trial name
- NCT00679718
- Testing
- diquafosol tetrasodium (INS365) ophthalmic solution
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye
Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye
Comparison of two Dry Eye products
- Trial name
- NCT00724412
- Testing
- Systane, Optive
- Volunteers
- 279 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Study of TL-925 as a Treatment for Dry Eye Disease
In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive…
- Trial name
- NCT05745064
- Testing
- TL-925
- Where
- 4 sites in United States
- Volunteers
- 107 people
- Sponsor
- Telios Pharma, Inc.
Dry Eye
Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18% in terms of cornea and…
- Trial name
- NCT03645850
- Testing
- Vismed gel Multi 0.3% eye drops, Vismed Multi 0.18% eye drops
- Volunteers
- 80 people
- Sponsor
- Horus Pharma
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
- Trial name
- NCT05403827
- Testing
- K-161
- Where
- 51 sites in United States
- Volunteers
- 644 people
- Sponsor
- Kowa Research Institute, Inc.
Dry Eye Syndromes
A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi®
SIFI SpA had developed Eyestil Plus®. It is sterile eyedrops without preservatives with a physiological pH containing sodium hyaluronate.
- Trial name
- 047/SI (NCT03803748)
- Testing
- Eyestil Plus®
- Where
- 12 sites in France, Spain
- Volunteers
- 96 people
- Sponsor
- SIFI SpA
Dry Eye Syndromes
3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
This study is a prospective, multicentre, parallel-group, active-controlled, non-inferiority study conducted in adult patients with moderate-to-severe dry eye disease (DED) related to keratitis or keratoconjunctivitis.
- Trial name
- ALHENA (NCT04685109)
- Testing
- Alocross 0.2% Unit Dose, Vismed
- Where
- 6 sites in France
- Volunteers
- 80 people
- Sponsor
- Santen SAS
Sjögren's Disease
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
- Trial name
- NCT07836660
- Testing
- Part B -Telitacicept, Part A - IBI355
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
- Trial name
- NCT06370039
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Invirsa, Inc.
Dry Eye
Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness
This study is a pilot, exploratory study to check safety and efficacy of DM-28 device, a new medical device intended to treat moderate to severe ocular dryness.
- Trial name
- NCT06607237
- Testing
- DM-28
- Where
- 2 sites in Poland
- Volunteers
- 44 people
- Sponsor
- Horus Pharma
Dry Eye Syndromes
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry…
- Trial name
- NCT02617667
- Testing
- Cyclosporine A
- Where
- 4 sites in United States
- Volunteers
- 207 people
- Sponsor
- Novaliq GmbH
Keratoconjunctivitis Sicca
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.
- Trial name
- NCT00128245
- Testing
- Pimecrolimus, Vehicle
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Novartis
Dry Eye Syndrome
Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients
The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry…
- Trial name
- NCT05245604
- Testing
- TJO-087, Cyclosporine ophthalmic solution 0.05%
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Dry Eye
To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops
This is a multi-site, randomized, investigator-masked study to evaluate the physical effects of Systane(R) versus Refresh Tears(R) in subjects with moderate to severe dry eye.
- Trial name
- NCT01160133
- Testing
- Systane, Refresh Tears
- Where
- India
- Volunteers
- 78 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes
The purpose of this study is to determine efficacy and safety of Haporine-S eye drop for the patients with moderate to severe dry eye disease in a multicenter phase III clinical trial.
- Trial name
- NCT01804361
- Testing
- Haporine-S, Restasis (cyclosporine 0.05%)
- Where
- 6 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- DH Bio Co., Ltd.
Dry Eye Disease
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive…
- Trial name
- NCT06225973
- Testing
- TL-925
- Where
- 18 sites in United States
- Volunteers
- 880 people
- Sponsor
- Telios Pharma, Inc.
Dry Eye Disease (DED)
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT07050446
- Testing
- Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops
- Where
- 3 sites in Serbia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Syndromes
Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease
- Trial name
- Cyclosporine (NCT01768312)
- Testing
- Cyclosporine ophthalmic solution
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Dry Eye Disease
Assessment of Efficacy and Safety of the Use of Two Eye Gel Products Containing 5% Dexpanthenol in Patients With Moderate to Severe Dry Eye Syndrome
The prospective, multicentric, randomized, non-inferiority, controlled, open-label clinical investigation will evaluate the efficacy and safety of the use of Myrialen® gel vs.
- Trial name
- NCT06210373
- Testing
- Myrialen Gel, Recugel
- Where
- 3 sites in Italy
- Volunteers
- 125 people
- Sponsor
- Fidia Farmaceutici s.p.a.